Qu Biologics

Qu Biologics is a clinical-stage biotechnology company dedicated to developing a novel proprietary immunotherapy platform, Site-Specific Immunomodulators (SSI). SSI aims to stimulate the innate immune response in targeted organs or tissues to reverse chronic inflammation caused by various diseases, including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSI is designed to restore immune function and has potential broad applicability across various chronic conditions.